4.6 Article

C9orf72 intermediate expansions of 24-30 repeats are associated with ALS

Journal

ACTA NEUROPATHOLOGICA COMMUNICATIONS
Volume 7, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s40478-019-0724-4

Keywords

C9orf72; Repeat expansion; ALS; Genetics; Whole-genome sequencing; Next-generation sequencing

Categories

Funding

  1. JPND (United Kingdom, Medical Research Council) [MR/L501529/1, MR/R024804/1]
  2. Economic and Social Research Council [ES/L008238/1]
  3. Motor Neurone Disease Association
  4. National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London
  5. European Community's Horizon 2020 Programme (H2020-PHC-2014-two-stage) [633413]
  6. MND Association
  7. Wellcome Trust
  8. NIHR Sheffield Biomedical Research Centre
  9. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  10. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  11. National Institute on Aging
  12. National Institute of Biomedical Imaging and Bioengineering
  13. AbbVie
  14. Alzheimer's Association
  15. Alzheimer's Drug Discovery Foundation
  16. Araclon Biotech
  17. BioClinica, Inc.
  18. Biogen
  19. Bristol-Myers Squibb Company
  20. CereSpir, Inc.
  21. Cogstate
  22. Eisai Inc.
  23. Elan Pharmaceuticals, Inc.
  24. Eli Lilly and Company
  25. EuroImmun
  26. F. Hoffmann-La Roche Ltd
  27. Genentech, Inc.
  28. Fujirebio
  29. GE Healthcare
  30. IXICO Ltd.
  31. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  32. Johnson & Johnson Pharmaceutical Research & Development LLC.
  33. Lumosity
  34. Lundbeck
  35. Merck Co., Inc.
  36. Meso Scale Diagnostics, LLC.
  37. NeuroRx Research
  38. Neurotrack Technologies
  39. Novartis Pharmaceuticals Corporation
  40. Pfizer Inc.
  41. Piramal Imaging
  42. Servier
  43. Takeda Pharmaceutical Company
  44. Transition Therapeutics
  45. Canadian Institutes of Health Research
  46. ESRC [ES/L008238/1] Funding Source: UKRI
  47. MRC [MC_PC_17115, MR/R024804/1, G0900688, MC_PC_17214, G0500289, G0600974, MR/L021803/1, G1100695, G0900635, UKDRI-6001] Funding Source: UKRI

Ask authors/readers for more resources

The expansion of a hexanucleotide repeat GGGGCC in C9orf72 is the most common known cause of ALS accounting for 40% familial cases and 7% sporadic cases in the European population. In most people, the repeat length is 2, but in people with ALS, hundreds to thousands of repeats may be observed. A small proportion of people have an intermediate expansion, of the order of 20 to 30 repeats in size, and it remains unknown whether intermediate expansions confer risk of ALS in the same way that massive expansions do. We investigated the association of this intermediate repeat with ALS by performing a meta-analysis of four previously published studies and a new British/Alzheimer's Disease Neuroimaging Initiative dataset of 1295 cases and 613 controls. The final dataset comprised 5071 cases and 3747 controls. Our meta-analysis showed association between ALS and intermediate C9orf72 repeats of 24 to 30 repeats in size (random-effects model OR=4.2, 95% CI=1.23-14.35, p-value=0.02). Furthermore, we showed a different frequency of the repeat between the northern and southern European populations (Fisher's exact test p-value=5x10(-3)). Our findings provide evidence for the association between intermediate repeats and ALS (p-value=2x10(-4)) with direct relevance for research and clinical practice by showing that an expansion of 24 or more repeats should be considered pathogenic.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available